-
Je něco špatně v tomto záznamu ?
MRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial
C. Pott, LH. Sehn, D. Belada, J. Gribben, E. Hoster, B. Kahl, B. Kehden, E. Nicolas-Virelizier, N. Spielewoy, G. Fingerle-Rowson, C. Harbron, K. Mundt, E. Wassner-Fritsch, BD. Cheson,
Jazyk angličtina Země Velká Británie
Typ dokumentu časopisecké články, práce podpořená grantem
NLK
ProQuest Central
od 2000-01-01 do Před 1 rokem
Open Access Digital Library
od 1997-01-01
Nursing & Allied Health Database (ProQuest)
od 2000-01-01 do Před 1 rokem
Health & Medicine (ProQuest)
od 2000-01-01 do Před 1 rokem
Public Health Database (ProQuest)
od 2000-01-01 do Před 1 rokem
- MeSH
- bendamustin hydrochlorid aplikace a dávkování MeSH
- doba přežití bez progrese choroby MeSH
- dospělí MeSH
- folikulární lymfom farmakoterapie MeSH
- humanizované monoklonální protilátky aplikace a dávkování MeSH
- lidé středního věku MeSH
- lidé MeSH
- nehodgkinský lymfom farmakoterapie MeSH
- protokoly protinádorové kombinované chemoterapie terapeutické užití MeSH
- reziduální nádor farmakoterapie MeSH
- rituximab aplikace a dávkování MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
We report assessment of minimal residual disease (MRD) status and its association with outcome in rituximab-refractory follicular lymphoma (FL) in the randomized GADOLIN trial (NCT01059630). Patients received obinutuzumab (G) plus bendamustine (Benda) induction followed by G maintenance, or Benda induction alone. Patients with a clonal marker (t[14;18] translocation and/or immunoglobulin heavy or light chain rearrangement) detected at study screening were assessed for MRD at mid-induction (MI), end of induction (EOI), and every 6-24 months post-EOI/discontinuation by real-time quantitative PCR. At MI, 41/52 (79%) patients receiving G-Benda were MRD-negative vs. 17/36 (47%) patients receiving Benda alone (p = 0.0029). At EOI, 54/63 (86%) patients receiving G-Benda were MRD-negative vs. 30/55 (55%) receiving Benda alone (p = 0.0002). MRD-negative patients at EOI had improved progression-free survival (HR, 0.33, 95% CI, 0.19-0.56, p < 0.0001) and overall survival (HR, 0.39, 95% CI, 0.19-0.78, p = 0.008) vs. MRD-positive patients, and maintained their MRD-negative status for longer if they received G maintenance than if they did not. These results suggest that the addition of G to Benda-based treatment during induction can significantly contribute to the speed and depth of response, and G maintenance in MRD-negative patients potentially delays lymphoma regrowth.
British Columbia Cancer Agency and the University of British Columbia Vancouver BC Canada
F Hoffmann La Roche Ltd Basel Switzerland
Georgetown University Hospital Washington DC USA
Hospital of the Ludwig Maximilians University Munich Germany
Queen Mary University of London London UK
University Hospital Schleswig Holstein Kiel Germany
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20025246
- 003
- CZ-PrNML
- 005
- 20201222153751.0
- 007
- ta
- 008
- 201125s2020 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/s41375-019-0559-9 $2 doi
- 035 __
- $a (PubMed)31462735
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Pott, Christiane $u University Hospital Schleswig-Holstein, Kiel, Germany. c.pott@med2.uni-kiel.de.
- 245 10
- $a MRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial / $c C. Pott, LH. Sehn, D. Belada, J. Gribben, E. Hoster, B. Kahl, B. Kehden, E. Nicolas-Virelizier, N. Spielewoy, G. Fingerle-Rowson, C. Harbron, K. Mundt, E. Wassner-Fritsch, BD. Cheson,
- 520 9_
- $a We report assessment of minimal residual disease (MRD) status and its association with outcome in rituximab-refractory follicular lymphoma (FL) in the randomized GADOLIN trial (NCT01059630). Patients received obinutuzumab (G) plus bendamustine (Benda) induction followed by G maintenance, or Benda induction alone. Patients with a clonal marker (t[14;18] translocation and/or immunoglobulin heavy or light chain rearrangement) detected at study screening were assessed for MRD at mid-induction (MI), end of induction (EOI), and every 6-24 months post-EOI/discontinuation by real-time quantitative PCR. At MI, 41/52 (79%) patients receiving G-Benda were MRD-negative vs. 17/36 (47%) patients receiving Benda alone (p = 0.0029). At EOI, 54/63 (86%) patients receiving G-Benda were MRD-negative vs. 30/55 (55%) receiving Benda alone (p = 0.0002). MRD-negative patients at EOI had improved progression-free survival (HR, 0.33, 95% CI, 0.19-0.56, p < 0.0001) and overall survival (HR, 0.39, 95% CI, 0.19-0.78, p = 0.008) vs. MRD-positive patients, and maintained their MRD-negative status for longer if they received G maintenance than if they did not. These results suggest that the addition of G to Benda-based treatment during induction can significantly contribute to the speed and depth of response, and G maintenance in MRD-negative patients potentially delays lymphoma regrowth.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a humanizované monoklonální protilátky $x aplikace a dávkování $7 D061067
- 650 _2
- $a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
- 650 _2
- $a bendamustin hydrochlorid $x aplikace a dávkování $7 D000069461
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a folikulární lymfom $x farmakoterapie $7 D008224
- 650 _2
- $a nehodgkinský lymfom $x farmakoterapie $7 D008228
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a reziduální nádor $x farmakoterapie $7 D018365
- 650 _2
- $a doba přežití bez progrese choroby $7 D000077982
- 650 _2
- $a rituximab $x aplikace a dávkování $7 D000069283
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Sehn, Laurie H $u British Columbia Cancer Agency and the University of British Columbia, Vancouver, BC, Canada.
- 700 1_
- $a Belada, David $u Department of Internal Medicine-Haematology, Charles University, Hospital and Faculty of Medicine, Hradec Králové, Czech Republic.
- 700 1_
- $a Gribben, John $u Queen Mary University of London, London, UK.
- 700 1_
- $a Hoster, Eva $u Hospital of the Ludwig-Maximilians University, Munich, Germany.
- 700 1_
- $a Kahl, Brad $u Washington University School of Medicine, St Louis, MO, USA.
- 700 1_
- $a Kehden, Britta $u University Hospital Schleswig-Holstein, Kiel, Germany.
- 700 1_
- $a Nicolas-Virelizier, Emmanuelle $u University of Lyon, Lyon, France.
- 700 1_
- $a Spielewoy, Nathalie $u F. Hoffmann-La Roche Ltd, Basel, Switzerland.
- 700 1_
- $a Fingerle-Rowson, Guenter $u F. Hoffmann-La Roche Ltd, Basel, Switzerland.
- 700 1_
- $a Harbron, Chris $u Roche, Welwyn Garden City, UK.
- 700 1_
- $a Mundt, Kirsten $u F. Hoffmann-La Roche Ltd, Basel, Switzerland.
- 700 1_
- $a Wassner-Fritsch, Elisabeth $u F. Hoffmann-La Roche Ltd, Basel, Switzerland.
- 700 1_
- $a Cheson, Bruce D $u Georgetown University Hospital, Washington, DC, USA.
- 773 0_
- $w MED00003138 $t Leukemia $x 1476-5551 $g Roč. 34, č. 2 (2020), s. 522-532
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31462735 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20201125 $b ABA008
- 991 __
- $a 20201222153747 $b ABA008
- 999 __
- $a ok $b bmc $g 1599391 $s 1115932
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 34 $c 2 $d 522-532 $e 20190828 $i 1476-5551 $m Leukemia $n Leukemia $x MED00003138
- LZP __
- $a Pubmed-20201125
